In fact, our discovery may be of fundamental biological significance as PLCγ2 is a critical signaling regulator of B-cell activation, whose hypoactivation could be used as a biomarker for response to therapies targeting the BCR signaling pathway, in CLL and other lymphoproliferative disorders. Here, PLCG2 is linked to B-cell chronic lymphocytic leukemia.